A new chemical entity (NCE) is, according to the U.S. Food and Drug Administration, a novel, small, chemical molecule drug that is undergoing clinical trials or has received a first approval (not a new use) by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.[1]
A new molecular entity (NME) is a broader term that encompasses both an NCE or an NBE (New Biological Entity).
YouTube Encyclopedic
-
1/3Views:3771 4301 269
-
NEW CHEMICAL ENTITY[NCE] Vs NEW MOLECULE ENTITY [NME] Pharmaceutical Concept [2021] | PC
-
What are Cannabinoid Analogs and Why are they Important?
-
505 (b)(2) Regulatory Pathway: Generic Drug Development Strategies
Transcription
Definition
An active moiety is a molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance.[2]
An NCE is a molecule developed by the innovator company in the early drug discovery stage, which after undergoing clinical trials could translate into a drug that could be a treatment for some disease. Synthesis of an NCE is the first step in the process of drug development. Once the synthesis of the NCE has been completed, companies have two options before them. They can either go for clinical trials on their own or license the NCE to another company. In the latter option, companies can avoid the expensive and lengthy process of clinical trials, as the licensee company would be conducting further clinical trials and subsequently launching the drug. Companies adopting this model of business would be able to generate high margins as they get a huge one-time payment for the NCE as well as entering into a revenue sharing agreement with the licensee company.
Under the Food and Drug Administration Amendments Act of 2007, all new chemical entities must first be reviewed by an advisory committee before the FDA can approve these products.
See also
References
- ^ "Archived copy" (PDF). Food and Drug Administration. Archived from the original (PDF) on 2017-02-09. Retrieved 2019-12-16.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "CFR – Code of Federal Regulations Title 21". United States Food and Drug Administration. 1 April 2018. Retrieved 15 February 2019.
External links
 | This article about medicinal chemistry is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 23 March 2024, at 22:33